185 followers
RT @FrontImmunol: New Research: Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cel…
RT @FrontImmunol: New Research: Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cel…
New Research: Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant: Background Chimeric antigen receptor (CAR) T-cell therapy… #immunology h
Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant https://t.co/XwwnpatbIW